Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial

INTRODUCTION: Patients with liver cirrhosis are often diagnosed late and once complications are present, the 2-year survival is 50%. Increasing evidence supports systemic inflammation and metabolic dysfunction in the hepatic stellate cell as key drivers of progression of cirrhosis. However, there is...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open
Egile Nagusiak: Kimer, Nina, Grønbæk, Henning, Fred, Rikard Gøran, Hansen, Torben, Deshmukh, Atul Shahaji, Mann, Mathias, Bendtsen, Flemming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Gastroenterology and Hepatology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045122/
https://ncbi.nlm.nih.gov/pubmed/31980514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-035284
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak